102 related articles for article (PubMed ID: 18987042)
1. Major US consumer group asks FDA to ban drug for diabetes.
Tanne JH
BMJ; 2008 Nov; 337():a2401. PubMed ID: 18987042
[No Abstract] [Full Text] [Related]
2. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Freemantle N
BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
[No Abstract] [Full Text] [Related]
3. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
4. Avandia panel member may be investigated for possible conflicts of interest.
Tanne JH
BMJ; 2010 Aug; 341():c4083. PubMed ID: 20682621
[No Abstract] [Full Text] [Related]
5. FDA places greater restrictions on access to rosiglitazone.
BMJ; 2010 Sep; 341():c5287. PubMed ID: 20870699
[No Abstract] [Full Text] [Related]
6. FDA committees say keep rosiglitazone available but increase warnings.
Tanne JH
BMJ; 2007 Aug; 335(7613):223. PubMed ID: 17673743
[No Abstract] [Full Text] [Related]
7. Licensing drugs for diabetes.
Lehman R; Yudkin JS; Krumholz H
BMJ; 2010 Sep; 341():c4805. PubMed ID: 20819887
[No Abstract] [Full Text] [Related]
8. Anticipated US approval for rosiglitazone and pioglitazone.
Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
[No Abstract] [Full Text] [Related]
9. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
10. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
11. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
12. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
13. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
14. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
15. Insiders criticise FDA's decision not to withdraw rosiglitazone.
Cohen D
BMJ; 2010 Sep; 341():c5333. PubMed ID: 20880925
[No Abstract] [Full Text] [Related]
16. US FDA approves three new drugs for Type 2 diabetes.
Bond T
Expert Rev Clin Pharmacol; 2013 Mar; 6(2):101. PubMed ID: 23593719
[No Abstract] [Full Text] [Related]
17. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
[No Abstract] [Full Text] [Related]
18. Is the FDA on drugs?
Calabresi M; Park A
Time; 2010 Aug; 176(8):24-8. PubMed ID: 20821962
[No Abstract] [Full Text] [Related]
19. Rosiglitazone: a case of regulatory hubris.
Nissen SE
BMJ; 2013 Dec; 347():f7428. PubMed ID: 24335808
[No Abstract] [Full Text] [Related]
20. Warner Lambert/Sankyo diabetes drug nears market.
Nat Biotechnol; 1997 Feb; 15(2):113. PubMed ID: 9035120
[No Abstract] [Full Text] [Related]
[Next] [New Search]
